Brief: Ocumension Therapeutics Completes Patient Enrollment In Phase III Clinical Trial Of OT-702
13/03/2023 14:33
March 13 (Reuters) - Ocumension Therapeutics 1477.HK :
* OCUMENSION THERAPEUTICS- PATIENT ENROLLMENT COMPLETED IN
PHASE
III CLINICAL TRIAL OF OT-702 IN CHINA
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application